Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedAug 15, 2018Prednisolone Sodium Phosphate Oral SolutionDefective Container: Tamper Evident foil seal not completely intact.Morton Grove Pharmaceuticals, Inc. · D-1042-2018Class IIITerminatedAug 15, 2018Diazepam Rectal GelLabeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.Valeant Pharmaceuticals North America LLC · D-1041-2018Class IITerminatedAug 15, 2018Kit for the Preparation of Technetium Tc99m MedronateLack of assurance of sterility: Technetium TC-99M Medronate Kit has a reported breach of sterility.Pharmalucence, Inc. · D-1040-2018Class IITerminatedAug 15, 2018Valsartan/HCTZ 320/25mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.NuCare Pharmaceuticals Inc · D-1039-2018Class IITerminatedAug 15, 2018Valsartan/HCTZ 160/25mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.NuCare Pharmaceuticals Inc · D-1038-2018Class IITerminatedAug 15, 2018Valsartan/HCTZ 160/12.5 mg TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.NuCare Pharmaceuticals Inc · D-1037-2018Class IIITerminatedAug 15, 2018Levofloxacin Injection in 5% DextroseSuperpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.Baxter Healthcare Corporation · D-1036-2018Class IIITerminatedAug 15, 2018Levofloxacin Injection in 5% DextroseSuperpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.Baxter Healthcare Corporation · D-1035-2018Class IIITerminatedAug 15, 2018Levofloxacin Injection in 5% DextroseSuperpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.Baxter Healthcare Corporation · D-1034-2018Class IIITerminatedAug 8, 2018Moxifloxacin Ophthalmic Solution USPFailed Impurities/Degradation Specifications: An out-of-specification result in the related substance test during three month long-term stability study.Lupin Pharmaceuticals Inc. · D-1050-2018Class IIITerminatedAug 8, 2018Fluconazole InjectionSuperpotent Drug: lots out of specification for elevated sodium chloride and fluconazole assay.Renaissance Lakewood, LLC · D-1033-2018Class IIITerminatedAug 8, 2018Fluconazole InjectionFailed Stability Specifications: lot out of specification for elevated water vapor.Renaissance Lakewood, LLC · D-1032-2018Class IIITerminatedAug 8, 2018Fluconazole InjectionSuperpotent Drug and Failed Stability Specifications: lot out of specification for elevated sodium chloride and elevated water vapor.Renaissance Lakewood, LLC · D-1031-2018Class IITerminatedAug 8, 2018Valsartan 320 mg tabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Bryant Ranch Prepack Inc. · D-1029-2018Class IITerminatedAug 8, 2018Valsartan 320 mg tabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Bryant Ranch Prepack Inc. · D-1028-2018Class IITerminatedAug 8, 2018Valsartan 80 mg tabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Bryant Ranch Prepack Inc. · D-1027-2018Class IITerminatedAug 8, 2018Doxycycline Hyclate TabletsFailed Dissolution SpecificationsMajor Pharmaceuticals · D-1026-2018Class IITerminatedAug 8, 2018Doxycycline Hyclate TabletsFailed Dissolution Specifications:West-Ward Columbus Inc · D-1025-2018Class IITerminatedAug 8, 2018Doxycycline Hyclate TabletsFailed Dissolution Specifications:West-Ward Columbus Inc · D-1024-2018Class IITerminatedAug 8, 2018Daptomycin for InjectionMicrobial Contamination of Sterile Products: Product associated with reports of adverse events indicative of infusion reactions related to microbiological contamination.Pfizer · D-1023-2018Class IITerminatedAug 8, 2018Valsartan tablets 160 mgCarcinogen impurity detected in API used to manufacture drug product.H J Harkins Company Inc dba Pharma Pac · D-1022-2018Class IITerminatedAug 8, 2018Valsartan/HCTZ 320mg/12.5 mg tabletCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1021-2018Class IITerminatedAug 8, 2018Valsartan/HCTZ 160 mg/12.5 mg tabletCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.RemedyRepack Inc. · D-1020-2018Class IITerminatedAug 8, 2018Indomethacin CapsulesFailed Tablet/Capsule Specifications: customer complaints of deformed, clumped, misshaped, melted or stuck together capsules.Hetero Labs, Ltd. - Unit III · D-1019-2018Class IITerminatedAug 8, 2018Potassium Citrate Extended-Release TabletsFailed Tablet/Capsule Specifications: Tablet breakageVensun Pharmaceuticals Inc · D-1018-2018Class IITerminatedAug 8, 2018Potassium Citrate Extended-Release TabletsFailed Tablet/Capsule Specifications: Tablet breakageVensun Pharmaceuticals Inc · D-1017-2018Class IIITerminatedAug 1, 2018Enalapril MaleateOut-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.Aidarex Pharmaceuticals LLC · D-0992-2018Class IIITerminatedAug 1, 2018Enalapril MaleateOut-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.Aidarex Pharmaceuticals LLC · D-0991-2018Class IIITerminatedAug 1, 2018Enalapril MaleateOut-of-specification results for the Enalapril Diketopiperazine degradation product during commercial stability.Aidarex Pharmaceuticals LLC · D-0990-2018Class IIOngoingAug 1, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0989-2018Class IIOngoingAug 1, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0988-2018Class IIOngoingAug 1, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0987-2018Class IIOngoingAug 1, 2018Valsartan TabletsCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0986-2018Class IIOngoingAug 1, 2018Valsartan and HydrochlorothiazideCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0985-2018Class IIOngoingAug 1, 2018Valsartan and HydrochlorothiazideCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0984-2018Class IIOngoingAug 1, 2018Valsartan and HydrochlorothiazideCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0983-2018Class IIOngoingAug 1, 2018Valsartan and HydrochlorothiazideCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0982-2018Class IIOngoingAug 1, 2018Valsartan and HydrochlorothiazideCGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.Teva Pharmaceuticals USA · D-0981-2018Class IIITerminatedAug 1, 2018Enalapril Maleate TabletsFailed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification...Major Pharmaceuticals · D-0980-2018Class IIITerminatedAug 1, 2018Enalapril Maleate TabletsFailed Impurities/Degradation Specifications: Sub-recall because this repackaged product was recalled by the manufacturing firm, Wockhardt, due to out-of-specification...Major Pharmaceuticals · D-0979-2018